William Blair analyst Matt Larew maintained a Hold rating on Amedisys (AMED – Research Report) today. The company’s shares closed yesterday at ...

Truist Financial analyst David S Macdonald maintained a Hold rating on Amedisys (AMED – Research Report) today and set a price target of ...

He also highlighted that the DOJ's review of UNH's purchase of LHC Group ... RBC's Hendrix raised his price target on ...

Shares of NASDAQ AMED opened at $92.60 on Wednesday. The company’s 50-day simple moving average is $90.11 and its 200-day simple moving average is $93.58. Amedisys has a 52-week low of $82.15 ...

"While UnitedHealth has acknowledged that the Amedisys deal is taking longer than expected, we believe the timing remains consistent with the longer-than-expected review of the (LHC Group ...

Amedisys, for the fourth quarter of 2024, delivers year-over-year top-line growth across three of its segments - Home Health, Hospice and High Acuity Care. While the top- and bottom-line numbers ...

Mutual of America Capital Management LLC decreased its position in shares of Amedisys, Inc. (NASDAQ:AMED – Free Report) by ...

Amedisys, for the fourth quarter of 2024, delivers year-over-year top-line growth across three of its segments - Home Health, ...

BATON ROUGE, La. (AP) — BATON ROUGE, La. (AP) — Amedisys Inc. (AMED) on Wednesday reported a fourth-quarter loss of $20.4 million, after reporting a profit in the same period a year earlier.